Response to W.C. Taylor, and C. Fiala and E.P. Diamandis

M. C. Liu; G. R. Oxnard; E. A. Klein; C. Swanton; M. Seiden

doi:10.1016/j.annonc.2020.06.008

Response to W.C. Taylor, and C. Fiala and E.P. Diamandis

M. C. Liu, G. R. Oxnard, E. A. Klein, C. Swanton, M. Seiden

Medical Oncology

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	1268-1270
Number of pages	3
Journal	Annals of Oncology
Volume	31
Issue number	9
DOIs	https://doi.org/10.1016/j.annonc.2020.06.008
State	Published - Sep 2020

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.annonc.2020.06.008

Cite this

@article{1836eee6209b4c8e9486e640d01d99e1,

title = "Response to W.C. Taylor, and C. Fiala and E.P. Diamandis",

author = "Liu, {M. C.} and Oxnard, {G. R.} and Klein, {E. A.} and C. Swanton and M. Seiden",

note = "Funding Information: The Mayo Clinic was compensated for MCL's advisory board activities for GRAIL, Inc. GRO reports personal fees from GRAIL, Inc. during the conduct of the study, as well as personal fees from Inivata, Sysmex, AstraZeneca, Janssen, Illumina, and Foundation Medicine outside the submitted work. EAK reports personal fees from GRAIL, Inc., during the design phase of the study. MS reports personal fees and other from McKesson and personal fees from GRAIL, Inc., during the conduct of the study; as well as other from Merck and Bristol Myers Squibb outside the submitted work. CS reports grants from Pfizer, AstraZeneca, BMS, Roche-Ventana, and Boehringer-Ingelheim; has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, and the Sarah Cannon Research Institute; has stock options of ApoGen Biotechnologies, Epic Bioscience, GRAIL, Inc.; and has stock options in and is cofounder of Achilles Therapeutics. CS is Royal Society Napier Research Professor. Editorial support provided by Megan P. Hall, PhD (GRAIL, Inc.). Funding Information: This work was supported by GRAIL, Inc . (Menlo Park, CA; no grant number). This publication was also partially supported by Princess Margaret Cancer Centre{\textquoteright}s McCain GU BioBank in the Department of Surgical Oncology (grant number REB # 08-0124); its contents are solely the responsibility of the authors and do not necessarily represent the official views of the University Health Network. CS is supported by the Francis Crick Institute that receives its core funding from Cancer Research UK [grant numbers FC001169, FC001202]; the UK Medical Research Council [grant numbers FC001169, FC001202]; and the Wellcome Trust [grant numbers FC001169, FC001202]. CS is funded by Cancer Research UK (TRACERx; PEACE; and CRUK Cancer Immunotherapy Catalyst Network, no grant number), the CRUK Lung Cancer Centre of Excellence (no grant number); the Rosetrees Trust (no grant number); and the Breast Cancer Research Foundation (BCRF, no grant number). ",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.06.008",

language = "English (US)",

volume = "31",

pages = "1268--1270",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Response to W.C. Taylor, and C. Fiala and E.P. Diamandis

AU - Liu, M. C.

AU - Oxnard, G. R.

AU - Klein, E. A.

AU - Swanton, C.

AU - Seiden, M.

N1 - Funding Information: The Mayo Clinic was compensated for MCL's advisory board activities for GRAIL, Inc. GRO reports personal fees from GRAIL, Inc. during the conduct of the study, as well as personal fees from Inivata, Sysmex, AstraZeneca, Janssen, Illumina, and Foundation Medicine outside the submitted work. EAK reports personal fees from GRAIL, Inc., during the design phase of the study. MS reports personal fees and other from McKesson and personal fees from GRAIL, Inc., during the conduct of the study; as well as other from Merck and Bristol Myers Squibb outside the submitted work. CS reports grants from Pfizer, AstraZeneca, BMS, Roche-Ventana, and Boehringer-Ingelheim; has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, and the Sarah Cannon Research Institute; has stock options of ApoGen Biotechnologies, Epic Bioscience, GRAIL, Inc.; and has stock options in and is cofounder of Achilles Therapeutics. CS is Royal Society Napier Research Professor. Editorial support provided by Megan P. Hall, PhD (GRAIL, Inc.). Funding Information: This work was supported by GRAIL, Inc . (Menlo Park, CA; no grant number). This publication was also partially supported by Princess Margaret Cancer Centre’s McCain GU BioBank in the Department of Surgical Oncology (grant number REB # 08-0124); its contents are solely the responsibility of the authors and do not necessarily represent the official views of the University Health Network. CS is supported by the Francis Crick Institute that receives its core funding from Cancer Research UK [grant numbers FC001169, FC001202]; the UK Medical Research Council [grant numbers FC001169, FC001202]; and the Wellcome Trust [grant numbers FC001169, FC001202]. CS is funded by Cancer Research UK (TRACERx; PEACE; and CRUK Cancer Immunotherapy Catalyst Network, no grant number), the CRUK Lung Cancer Centre of Excellence (no grant number); the Rosetrees Trust (no grant number); and the Breast Cancer Research Foundation (BCRF, no grant number).

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85089287097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089287097&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.06.008

DO - 10.1016/j.annonc.2020.06.008

M3 - Letter

C2 - 32569726

AN - SCOPUS:85089287097

SN - 0923-7534

VL - 31

SP - 1268

EP - 1270

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -

Response to W.C. Taylor, and C. Fiala and E.P. Diamandis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this